ࡱ> KJ T8\p#Williams, Walter W. (CDC/OID/NCIRD)R) Ba==pby,8X@"1Calibri1Calibri1Calibri1Calibri1& Courier New1& Courier New1& Courier New1& Courier New1& Courier New1& Courier New1& Courier New1& Courier New1Calibri1 Calibri1Calibri14Calibri1 Calibri1Calibri1Calibri1Calibri1,8Calibri18Calibri18Calibri1 Calibri1>141<Calibri1?Calibri1h8Cambria1Calibri1 Calibri1& Courier New1& Courier New1& Courier New1& Courier New"$"#,##0_);\("$"#,##0\)!"$"#,##0_);[Red]\("$"#,##0\)""$"#,##0.00_);\("$"#,##0.00\)'""$"#,##0.00_);[Red]\("$"#,##0.00\)7*2_("$"* #,##0_);_("$"* \(#,##0\);_("$"* "-"_);_(@_).))_(* #,##0_);_(* \(#,##0\);_(* "-"_);_(@_)?,:_("$"* #,##0.00_);_("$"* \(#,##0.00\);_("$"* "-"??_);_(@_)6+1_(* #,##0.00_);_(* \(#,##0.00\);_(* "-"??_);_(@_)0.0"Yes";"Yes";"No""True";"True";"False""On";"On";"Off"],[$ -2]\ #,##0.00_);[Red]\([$ -2]\ #,##0.00\) 0.0E+00#[$-409]dddd\,\ mmmm\ d\,\ yyyy[$-409]h:mm:ss\ AM/PM                                                                       ff  +  )  ,  *      P  P         `             a>      " !)| ! (@ @  "<@ @  "8 "< ! !\ !"\ ")8 !" ")x ! " !8 "<@ @  ! "< ! < ! ""<  "<@ @  " 8@ @  "*<@ @  "*< "*| !*<  ) !) #) !) !8 #8 !)x "8 "*<@ @  ")8@ @  !(8 ||f3?}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-} yyy0_)}-}  yyy0_)}-}  yyy0_)}-}  yyy0_)}-}  yyy0_)}-}  yyy0_)}-} yyy0_)}-} yyy0_)}A} yyy0_)ef[$ -}A} yyy0_)ef[$ -}A} yyy0_)ef[$ -}A} yyy0_)ef[$ -}A} yyy0_)ef[$ -}A} yyy0_)ef [$ -}A} yyy0_)L[$ -}A} yyy0_)L[$ -}A} yyy0_)L[$ -}A} yyy0_)L[$ -}A} yyy0_)L[$ -}A} yyy0_)L [$ -}A} yyy0_)23[$ -}A} yyy0_)23[$ -}A} yyy0_)23[$ -}A} yyy0_)23[$ -}A}  yyy0_)23[$ -}A}! yyy0_)23 [$ -}A}" yyy0_)[$ -}A}# yyy0_)[$ -}A}$ yyy0_)[$ -}A}% yyy0_)[$ -}A}& yyy0_)[$ -}A}' yyy0_) [$ -}A}( yyy0_)[$ -}}) }yyy0_)[$ -##0.  }}* yyy0_)[$ -???##0.??? ??? ???}-}+ yyy0_)}-}, yyy0_)}-}- yyy0_)}-}. yyy0_)}-}/ yyy0_)}-}0  yyy0_)}A}1 ayyy0_)[$ -}A}2 yyy0_)[$ -}A}3 yyy0_)?[$ -}A}4 yyy0_)23[$ -}-}5 yyy0_)}-}6  yyy0_)}}7 ??vyyy0_)̙[$ -##0.  }A}8 }yyy0_)[$ -}A}9 eyyy0_)[$ -}-}: yyy0_)}}; yyy0_)[$ -##0.  }}< ???yyy0_)[$ -???##0.??? ??? ???}-}= yyy0_)}-}> yyy0_)}U}? yyy0_)[$ -##0.}-}@ yyy0_)}(}A yyy0_)}(}B yyy0_)}(}C yyy0_)}(}D yyy0_)}(}E yyy0_)}(}F yyy0_)}(}G yyy0_)}(}H yyy0_)}(}I yyy0_)}(}J yyy0_)}(}K yyy0_)}(}L yyy0_)}(}M yyy0_)}(}N yyy0_)}(}O yyy0_)}(}P yyy0_)}(}Q yyy0_)}(}R yyy0_)}(}S yyy0_)}(}T yyy0_)}(}U yyy0_)}(}V yyy0_)}(}W yyy0_)}(}X yyy0_)}(}Y yyy0_)}(}Z yyy0_)}(}[ yyy0_)}(}\ yyy0_)}(}] yyy0_)}(}^ yyy0_)}(}_ yyy0_)}(}` yyy0_)}(}a yyy0_)}(}b yyy0_)}(}c yyy0_)}(}d yyy0_)}(}e yyy0_) 20% - Accent1M 20% - Accent1 ef % 20% - Accent2M" 20% - Accent2 ef % 20% - Accent3M& 20% - Accent3 ef % 20% - Accent4M* 20% - Accent4 ef % 20% - Accent5M. 20% - Accent5 ef % 20% - Accent6M2 20% - Accent6  ef % 40% - Accent1M 40% - Accent1 L % 40% - Accent2M# 40% - Accent2 L渷 % 40% - Accent3M' 40% - Accent3 L % 40% - Accent4M+ 40% - Accent4 L % 40% - Accent5M/ 40% - Accent5 L % 40% - Accent6M3 40% - Accent6  Lմ % 60% - Accent1M 60% - Accent1 23 % 60% - Accent2M$ 60% - Accent2 23ږ % 60% - Accent3M( 60% - Accent3 23כ % 60% - Accent4M, 60% - Accent4 23 % 60% - Accent5M0 60% - Accent5 23 %! 60% - Accent6M4 60% - Accent6  23 % "Accent1AAccent1 O % #Accent2A!Accent2 PM % $Accent3A%Accent3 Y % %Accent4A)Accent4 d % &Accent5A-Accent5 K % 'Accent6A1Accent6  F %(Bad9Bad  %) Calculation Calculation  }% * Check Cell Check Cell  %????????? ???+ Comma,( Comma [0]-&Currency.. Currency [0]/Explanatory TextG5Explanatory Text %0 K Followed Hyperlink  % 1Good;Good  a%2 Heading 1G Heading 1 I}%O3 Heading 2G Heading 2 I}%?4 Heading 3G Heading 3 I}%235 Heading 49 Heading 4 I}%69 Hyperlink  % 7InputuInput ̙ ??v% 8 Linked CellK Linked Cell }% 9NeutralANeutral  e%3Normal % :Normal 57Normal 5 % ;Noteb Note   <OutputwOutput  ???%????????? ???=$Percent >Title1Title I}% ?TotalMTotal %OO@ Warning Text? Warning Text %XTableStyleMedium9PivotStyleLight16`!_Box4_Table 9 Ins-adjusteda| cV 19-26 yrse"19 yrse"65 yrs19-64 yrs, increased risk-Vaccination, age group, increased-risk statuse"60 yrs (95% CI) 19-49 yearsWith health insuranceWithout health insurance%Tetanus vaccination, past 10 years***A Tetanus vaccination including pertussis vaccine, past 10 years > 3Hepatitis A vaccination (at least 2 doses), ever0 e"19 yrs, all adults e"19 yrs, traveler4Hepatitis B vaccination (at least 3 doses), ever****e"19 yrs, with diabetes. Herpes zoster (shingles) vaccination, ever * 9HPV vaccination among females (at least 1 dose), ever5 7HPV vaccination among males (at least 1 dose), ever3 >* Adults were considered at increased risk for pneumococcal disease if they had ever been told by a doctor or other health professional that they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other heart condition; had a diagnosis of cancer during the previous 12 months (excluding nonmelanoma skin cancer); had ever been told by a doctor or other health professional that they had lymphoma, leukemia, or blood cancer; had been told by a doctor or other health professional that they had chronic bronchitis or weak or failing kidneys during the preceding 12 months; had an asthma episode or attack during the preceding 12 months; or were current smokers. For hepatitis A and hepatitis B vaccination, data were collected on selected respondent characteristics that increase the risk for infection (travel to countries where hepatitis A infections are endemic and having chronic liver disease; having diabetes, travel to countries where hepatitis B infections are endemic, and having chronic liver disease, respectively).*** Respondents were asked if they had received a tetanus shot in the past 10 years. Vaccinated respondents included adults who received Td or Tdap during the past 10 years. Respondents were asked if they had ever received the hepatitis A vaccine, and if yes, were asked how many doses were received. Had traveled outside the United States to countries other than countries in Europe, Japan, Australia, New Zealand, or Canada since 1995.**** Respondents were asked if they had ever received the hepatitis B vaccine, and if yes, if they had received at least 3 doses or less than 3 doses.I  Respondents were asked if they had ever received a shingles vaccine.fHPV vaccination among females (at least 1 dose), ever who reported first HPV dose at 19-26 yrs5 :b dHPV vaccination among males (at least 1 dose), ever who reported first HPV dose at 19-26 yrs3 8`   Adults were considered insured if they reported having public health insurance coverage (Medicare, Medicaid, military health care [TRICARE/VA/CHAMP-VA], Indian Health Service, state-sponsored health plan, or other government program insurance) or private health insurance coverage.@ Respondents were asked if they had ever had a pneumonia shot.#  Respondents who reported receiving a tetanus shot in the past 10 years were asked if their most recent shot included the pertussis or whooping cough vaccine. Among 26,430 respondents e"19 years, those without a "yes" or "no" classification for tetanus vaccination status within the preceding 10 years (n = 1,562 [5.9%]), those who reported tetanus vaccination in the past 10 years but were not told vaccine type by the provider (n = 6,967 [26.4%]), did not know vaccine type (Td or Tdap) (n = 2,359 [8.9%]), or refused to answer or for whom data were not obtained (n=6 [0.02%]) were excluded, yielding a sample of 15,536 respondents e"19 years for whom Tdap vaccination status could be assessed. In February 2012, ACIP recommended Tdap vaccination for all adults e"19 years, including adults e"65 years.Adjusted vaccination coverage Adjusted vaccination coverageAdjusted prevalence ratio (95% CI) Adjusted prevalence difference**( Influenza vaccination (2016-17 season) & (43.2-45.1) (29.7-36.0) (0.8-0.9) !Pneumococcal vaccination, ever  (22.7-25.7) (18.3-27.4) (0.9-1.0) (67.5-70.7) (28.5-85.2) (0.4-1.4) (62.6-65.0) (61.1-67.0) (0.9-1.1) (30.8-33.7) (26.2-33.3) (10.7-12.3) (6.0-9.5) (0.9-1.0)  (17.0-19.8) (8.2-16.7) (25.6-27.6) (20.0-25.1) (33.7-36.8) (26.7-33.7) (15.9-20.4) (9.6-26.4) (33.9-36.8) (3.4-14.3) (0.7-0.8)  (47.8-55.5) (46.2-66.5) (0.9-1.4) (16.8-23.4) (14.9-35.0) (0.9-1.2) (6.0-11.2) (4.9-20.2) (1.0-1.1) (6.8-12.9) (5.5-23.3)Abbreviations: CI = confidence interval; HPV = Human papillomavirus; Td = Tetanus and diphtheria toxoids; Tdap = Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.n Adjusted coverage estimates are based on predicted marginals from a multivariable logistic regression model. Estimates were adjusted for age, gender, race/ethnicity, marital status, education, employment status, poverty level, number of physician contacts in the past year, usual source of care, self-reported health status, nativity, and region of U.S. residence. "With health insurance" is the reference group. The adjusted prevalence ratio is calculated by dividing adjusted vaccination coverage among those without health insurance by adjusted coverage among those with health insurance.t** Adjusted coverage among those with health insurance minus adjusted coverage among those without health insurance.J  Respondents were asked if they had received an influenza vaccine in the past 12 months and if so, in which month and year. Missing month and year were imputed (3.6%) and interviews conducted during August 2016 June 2017 were used to estimate vaccination coverage during July 2016 May 2017 using Kaplan Meier survival analysis.  p<0.05 by t-test comparing adjusted coverage among those with health insurance to adjusted coverage among those without health insurance. Respondents were asked if they had ever received the HPV shot or cervical cancer vaccine, and if yes, age at the first dose.  The denominator includes persons aged 19 26 years without HPV vaccination prior to age 19 years, and the<r numerator includes those in the denominator who reported first HPV dose at age 19 26 years.  BOX 4_ Disparities /TABLE 9. Adjusted vaccination coverage among adults aged e"19 years, by age group, increased-risk status,* and health insurance status  National Health Interview Survey, United States, 2017 Z< S=?d5F cQ_RREYSS%8TWccB T8 .an4r  dMbP?_*+%,&ffffff?'ffffff?(?)?",B333333?333333?d&<3U} I6} } } } } $} } } .  @ @ u@ ; ; @ , , @ , X@ , @ ; ; v@ ; ; , @ ; @ , @ , @ , @ , X@ @ @ bUbbbbbbbbD c cE c cEEU V W WP W W W! W" W# F$TTGGGGGG H~ L:@ L%S~ S@ S&~ ST@ S'~ L@ K(XLSSSSSS H~ L@ L)S~ S@ S*~ S? S+~ S@`@ HLfffffFQ@ L,S~ S:@ S-~ SQ@ S.~ S@ M YBBBBBSS H~ L@ L/ S IfffffP@ I0~ S? S1~ S> K  XLSSSSSS H Lfffff&@@ L2 S~ S4@ S3~ S? S+~ S@ K  XLSSSSSS H ~ Z'@ L4 S~ S`@ S5~ S? S6~ S w@ HZffffff2@ L7S~ I`@ I8~ SV@ S6~ S@ KBBBBBBBB H ~ ZȤ@ L9S~ S@ S:~ SV@ S6Sffffff@ HLfffffA@ L;S~ S@ S<~ SV@ S6~ S@ H~ Lp@ L=S~ S2@ S>~ S? S1~ S4@ KXLSSSSSS H~ J@ J?S~ SЋ@ S@~ SQ@ SA~ S:@ KXLSSSSSS H~ L(@ NBS~ N@ NCN? ND~ N~ KBLSSSSSS ON4@ NES~ Nt@ NFN? NG~ N~ KXQRRRRRR H~ N@ NHS~ N@ NI~ N? NJ~ N KXQRRRRRR ON#@ NKS~ N@ NLN? NGNffffff dMdddddddd _________ eeeeeeeeeD l(Fz(z(z~(~(~(z~(~~z(z(~((z((( f@! @" @# *@$ @% J@& @' @( @) @* +@+ h@, @- @ _N ________ !`O!```````` "_P"________ #aQ#aaaaaaaa $\R$\\\\\\\\ %a%aaaaaCBB &\&\\\\\\\\ ']'\\\\\\\\ (^(^^^^^^^^ )\)\\\\\\\\ *^*^^^^^^^^ +\+\\\\\\\\ ,AS,BBBBBBBB -[T-[[[[[[[[ H(((((((((((((>!@[Z555 !!""##$$%%--&&''(())**++ggD Oh+'0HP` sig6(Hung, Mei-Chuan (CDC/OID/NCIRD) (CTR)Microsoft Excel@U@Lj@dд ՜.+,0 PXd lt| CDC Box4_Table 9 Ins-adjusted  Worksheets  !"#$%&'()*+,-./0123456789;<=>?@ACDEFGHIRoot Entry FGj[WorkbookRsSummaryInformation(:DocumentSummaryInformation8B